Satellos Bioscience’s New DMD Data Fuels $18 Target, Boosting Skeletal Muscle Regeneration Hope
Satellos Bioscience’s SAT‑3247 shows breakthrough muscle‑regeneration results in DMD, boosting investor confidence and pricing the stock for a potential game‑changing therapy.
4 minutes to read
